BioTime takes exclusive license on Cornell embryonic vascular stem cell technology
This article was originally published in Scrip
Executive Summary
BioTime has entered into an exclusive licence agreement with Cornell University for the worldwide development and commercialisation of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells.